• Consider Micron (MU) and SanDisk (SNDK) only as cautious, higher-volatility opportunities after the semiconductor selloff; confirm demand and upcoming results support the investment case before buying.
• Avoid Intel (INTC) for now; the commentary was explicitly bearish, with improved execution and guidance needed before reconsidering.
• For NVIDIA (NVDA) and other AI chip stocks, watch customer spending and whether AI infrastructure investment translates into revenue; no specific entry price or target was provided.

Semiconductor stocks and ETFs

• AMD (AMD), SanDisk (SNDK), Qualcomm (QCOM), Arm (ARM), Micron (MU), Intel (INTC), and the semiconductor ETF SMH were discussed amid a sharp sector selloff. The speaker described the group as cyclical and sensitive to changes in demand, with investors crowded into semiconductor and technology stocks.
• The speaker said the downturn could create buying opportunities in SanDisk and Micron, while emphasizing that it was difficult to tell whether the selling was panic or a rational reassessment.
• He was notably negative on Intel, saying he did not like it and thought it was the wrong time to enter; he also said Intel needed a new CEO.
• The discussion framed the key question as whether chip companies can meet or exceed earnings and revenue expectations—not whether AI is transformative. The speaker said the AI boom was not necessarily over, but investors should watch whether AI growth and customer spending meet expectations.
• The transcript includes a mock margin-call exchange about leveraged Micron positions, but the speaker later clarified that he had no Micron call options and was joking.

Takeaways

• Treat the semiconductor selloff as a sign of elevated volatility and crowded positioning, not proof by itself that the sector is either a bargain or fundamentally broken.
• For individual chip stocks, focus on demand, customer spending, and upcoming results relative to expectations. The speaker’s positive comments about Micron and SanDisk were tentative; his view on Intel was explicitly negative.
• Avoid treating the mock margin-call story as a real trade or recommendation. It does, however, illustrate how leverage can magnify losses during a sharp decline.

NVIDIA (NVDA)

• NVIDIA was among the semiconductor stocks falling during the selloff. The speaker said its outlook depends importantly on whether its customers remain confident and continue buying.
• He noted that Meta was still buying, but raised the possibility that other customers could pause or change spending plans. He also questioned whether the hardware boom would be supported by enough growth in AI software and services.

Takeaways

• Monitor customer spending and the conversion of AI infrastructure investment into revenue, rather than relying only on broad enthusiasm for AI.
• The transcript gives no price target or specific entry point for NVIDIA.

Intel (INTC)

• Intel was described as a weak spot during the semiconductor decline. The speaker said he did not like the stock and thought it was the worst time to get into it, adding that the company needed a new CEO.
• He also pointed to the importance of Intel meeting future earnings and revenue guidance.

Takeaways

• The speaker’s stance was bearish. For a general investor, the discussion suggests watching for evidence of improved execution and guidance before assuming a lower share price represents an opportunity.

Rhythm Pharmaceuticals (RYTM) and AstraZeneca (AZN)

• The speaker said Rhythm Pharmaceuticals was rumored to be acquired by AstraZeneca, and that Rhythm’s stock had surged the prior day.
• The acquisition was presented as a rumor, not a confirmed transaction.

Takeaways

• Treat acquisition speculation cautiously: the potential upside depends on a deal actually being announced and completed. The transcript provides no confirmed terms or recommendation.

Edgewise Therapeutics (EWTX)

• The speaker discussed Edgewise Therapeutics, whose drug candidate is being studied for hypertrophic cardiomyopathy. He referenced a Phase 3 program, the STRATUS protocol, and peak VO₂ as the primary endpoint, with initiation planned by year-end.
• He described the company as having a roughly $5 billion market capitalization and $3.3–$3.4 billion enterprise value, while noting that trials would require substantial spending.
• He questioned how differentiated Edgewise’s drug was from drugs being developed by Bristol Myers Squibb and Cytokinetics. He also described the shareholder base as crowded with specialist healthcare investors.

Takeaways

• The investment case depends on clinical-trial results, differentiation from competing treatments, and the cost of advancing the program.
• The speaker expressed interest in examining the company but did not offer a clear buy recommendation.

Savara (SVRA)

• The speaker noted that Savara had received an approval. No further details about the approved product, market opportunity, or share-price outlook were provided.

Takeaways

• Approval can be an important milestone, but the transcript does not provide enough information to assess commercial prospects or value the stock.

SELLAS Life Sciences (SLS)

• The speaker called SLS a short and described it as having no value, expressing strongly bearish sentiment.

Takeaways

• This was an emphatic negative opinion, not a substantiated investment analysis in the transcript. The speaker gave no supporting details or price target, so it should not be treated as a standalone basis for a short position.

Moderna (MRNA)

• The speaker mentioned Moderna in the context of earnings and said he did not have much to add. He described demand as unusually high but also said the company was heavily owned, including by retail investors.
• He noted that the drug being discussed was not FDA-approved, without specifying which drug or offering further clinical or commercial detail.

Takeaways

• The transcript offers no clear directional recommendation. Investors would need to assess product approval prospects, demand, and the company’s expectations independently.

Bristol Myers Squibb (BMY) and its medicines

• The speaker said Bristol Myers Squibb appeared to be executing well. He noted that about 15% of Opdivo had shifted to Opdivo Qvantig.
• He described Reblozyl as continuing to grow, Breyanzi as a strong cell-therapy product with roughly $2 billion in sales, and Opdualag as performing well. He cited Camzyos at about $1.6 billion and called Eliquis’s reported growth strong, including growth of 26% as it approached expiry.
• He also characterized Reblozyl’s outcome as disappointing relative to expectations, despite continued growth.

Takeaways

• The discussion was broadly positive on Bristol Myers’ execution and several products, but it also highlighted that growth and expectations can differ by drug.
• The transcript gives no stock-price target or explicit recommendation on BMY.

Cytokinetics (CYTK) and Zura Bio (ZURA)

• Cytokinetics was mentioned as developing a drug in the same indication as Edgewise.
• The speaker said Zura Bio had a “binary event,” indicating a potentially consequential upcoming catalyst, but did not provide details.

Takeaways

• For both companies, the transcript points to clinical or event-driven risk but gives no specific data, timeline, or investment recommendation. A binary catalyst can lead to large moves in either direction.

Unity (U)

• Unity was noted as rising 18% during the session. No explanation for the move or assessment of its business was provided.

Takeaways

• The transcript offers no investment thesis beyond the reported price move; do not infer that the speaker endorsed the stock.

Apple (AAPL)

• Apple was said to have been up roughly 30% the prior night and about 23% at the time of the comment. The transcript does not explain the move or offer a view on the company.

Takeaways

• The reported move alone is not a basis for an investment decision. No recommendation or valuation discussion was provided.

Marvell Technology (MRVL)

• The speaker said a deal involving Marvell was probably not going to go through, reasoning that Wall Street appeared less enthusiastic about it than the company was. He said Marvell might try to sell the deal more convincingly, but left the outcome uncertain.

Takeaways

• The commentary suggests uncertainty around the transaction and the market’s reception of it. The transcript does not identify the deal terms or provide a stock recommendation.

CoreWeave and Cerebras

• Asked which company had the most data-center exposure, the speaker suggested CoreWeave. He said Cerebras was not at the bottom, without giving further detail.
• He later said market conditions might lead to a delay of the Anthropic IPO, and noted that buyers would need to be available for an IPO to proceed.

Takeaways

• The discussion highlights exposure to data-center investment and the importance of capital-market conditions for potential listings.
• The speaker gave no valuation or recommendation for CoreWeave or Cerebras.

Palantir (PLTR)

• The speaker said Palantir had exceeded earnings expectations but its stock still fell, using it as an example of a difficult market environment in which strong results may not be enough.

Takeaways

• Pay attention to the gap between reported results and investor expectations. A company can beat expectations and still see its share price decline when market sentiment is weak.

Alphabet / Google (GOOG, GOOGL)

• Google was mentioned in connection with a reported $17 billion data-center investment.
• The speaker also referred to Google and Intel falling after results or guidance that disappointed investors, and discussed the possibility that AI spending and returns may not develop as quickly as expected.

Takeaways

• The discussion raises the question of whether substantial AI and data-center spending will produce growth that meets investor expectations. No specific view on Alphabet’s stock was given.

Walmart (WMT), Procter & Gamble (PG), and McDonald’s (MCD)

• The speaker said Walmart was not a great place to rotate into during the selloff. He mentioned Procter & Gamble as a countercyclical or noncyclical example, while cautioning that it was not cheap.
• McDonald’s came up in a question about historical price data, not as an investment recommendation.

Takeaways

• Defensive stocks may be considered when risk appetite falls, but the speaker cautioned that some are still expensive. The transcript does not identify a preferred defensive stock.

Quantum-computing companies

• The speaker said valuations for quantum companies were close to zero, in his view, and described their share prices as being driven more by capital flows than by conventional valuation.

Takeaways

• The comments point to speculative, sentiment-driven behavior in the theme. Investors should be cautious about relying on broad sector enthusiasm without assessing individual companies’ fundamentals.

Bitcoin (BTC) and Hyperliquid

• Bitcoin was mentioned as falling during the market turmoil. No price level or broader crypto outlook was provided.
• Hyperliquid was mentioned in a political comment, without discussion of its token or investment merits.

Takeaways

• The transcript gives no actionable crypto thesis. A reported decline in Bitcoin is an observation, not a buy or sell recommendation.

Anthropic and OpenAI

• The speaker said market conditions could delay an Anthropic IPO, emphasizing that sufficient buyers would need to be present.
• He also said OpenAI had reduced the size of a new offering and suggested it could shrink further. He framed the broader question as whether AI growth would meet the high expectations built into the market.

Takeaways

• The discussion highlights listing and fundraising risk for private AI companies when public-market demand weakens.
• These are private-company opportunities, not publicly traded stocks in the transcript, and no investment terms or recommendation were provided.

Anduril and Spruce Bio

• The speaker expressed enthusiasm for Anduril, but did not explain the investment case.
• He mentioned Spruce Bio and its holders but offered no substantive view on the company.

Takeaways

• The transcript does not provide enough information to support an investment conclusion on either company.